Biohaven (NYSE:BHVN) Selling and Marketing Expense

: $0.00 Mil (TTM As of Sep. 2022)

View and export this data going back to 2022. Start your Free Trial

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Biohaven's Selling and Marketing Expense for the three months ended in Sep. 2022 was $0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00 Mil.

Biohaven Selling and Marketing Expense Historical Data

The historical data trend for Biohaven's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data

Trend

Dec20

Dec21

Selling and Marketing Expense

Biohaven Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22
Selling and Marketing Expense		-	-	-	-	-

Biohaven Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Biohaven Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Biohaven's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven (NYSE:BHVN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Selling and Marketing Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 Church Street, New Haven, CT, USA, 06510

Website

https://www.biohavenpharma.com

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.

Executives

George C. Clark	officer: VP, Chief Accounting Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
Kimberly Gentile	officer: SVP, Clinical Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs	director	111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric	director, officer: Chief Executive Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic	director	215 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten	officer: Chief Financial Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta	director	540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd.	10 percent owner	215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car	officer: Chief Scientific Officer	AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139